Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: J Control Release. 2022 Jan 22;343:142–151. doi: 10.1016/j.jconrel.2022.01.023

Figure 1:

Figure 1:

Overview of the Tissue Reactive Anchoring of Pharmaceutics (TRAPs) technology. An injectable prodrug consisting of a drug (red) conjugated to an anchoring motif (blue) through a cleavable linker (green) is injected locally. When injected into tissues, the anchor reacts with tissue extracellular matrix (ECM), anchoring the drug to the tissues. Over time, the linker connecting the drug to the ECM slowly dissolves, releasing drug in the tissue.